




Parkinson’s disease (PD) is a serious disease 
and economic and social problems of present 
times. It is caused by the loss of dopamine-
producing neurons and by the accumulation 
of a protein into Lewy bodies in neurons in 
the area of midbrain, in the so-called pars 
compacta substantia nigra. In fact, before this 
disease breaks out, there is a loss of 60-80% 
of dopaminergic neurons (Farlow et al., 
2013). There is thus a relatively long period 
of time preceding the actual manifestation of 
motor symptoms at which point a substantial 
proportion of dopaminergic cells has been 
already lost with no movement-related issues 
being evident. Therefore, a detailed neurological 
and laboratory examination of patients suffering 
from impaired olfaction and sleep disturbances 
would bring a signifi cant benefi t to PD diagnosis 
in its early stage. The fi rst symptoms of this 
disease comprise overall tremor, particularly in 
hands, slowness of movement, rigidity of limbs, 
and balance diffi culties (Ransmayr, 2015).
Sometimes these symptoms are described 
by acronyms TRAP (Tremor, Rigidity, Aknesis 
and Posture instability) (Yorkston, Beukelman, 
Strand, & Bell, 1999). These key motor 
symptoms are also called Parkinsonism or 
a parkinsonian syndrome. In addition, besides 
the motor symptoms, in the course of the 
development of PD patients might acquire 
other disorders known as non-motor symptom 
complex which includes cognitive diffi culties 
and dementia; neuropsychiatric symptoms 
such as depression, anxiety, hallucinations 
or apathy; autonomic symptoms such as low 
blood pressure, constipation, diffi culties in 
swallowing, increased sweating or sexual 
dysfunction; sleep disorders; or loss of smell. 
This disease mostly affects older people 
(60+). According to the study of 2012, about 
4.1-4.6 million people suffered from PD 
worldwide (Dorsey et al., 2007). Currently, 
almost 6.3 million of people are affected by 
this disease (European Parkinson’s Disease 
Association, 2015). More than one million of 
the Europeans has it and there are forecasts 
that by 2030 a number of patients will double. 
Despite the fact that the impact of Parkinson’s 
disease on present society is enormous, many 
people are not well informed about this disease.
Experts warn against the increasing 
frequency of Parkinson’s disease with the 
person’s growing age. This increase is quite 
obvious until person is 75 years old. After that, 
the increase is not that much striking (European 
Parkinson’s Disease Association, 2015). An 
average age of the onset of the disease is around 
57 years. That is why Parkinson’s disease is 
considered to be an aging disease (Drummond 
& O’Brien, 1997). Out of the whole population 
older than 60 years, 1% of people suffer from 
this disease (“Všeobecná Zdravotní Pojišťovna 
[General Health Insurance Company],” 2015). 
As many as 10% of patients fall ill before they 
are 40. This is an early onset of the disease 
(young onset type). In this case, the calendar 
age is not important, but it is the biological 
age of an individual, which is infl uenced by his 
genetics. Another 10% fall ill after they are 75, 
which is a late onset of the disease (late onset 
type) (Růžička, Roth, & Kaňovský, 2000).
From the point of view of public systems of 
many countries in Europe, it can be said that 
care about people with dementia is done in 
mutually separated sectors. A part of this care is 
provided by healthcare system, as in the case of 
other mental health diseases the majority of the 
cost of disease are not born in the healthcare 
system (Dlouhý, & Barták, 2013) and part by 
social services. A specifi c interface of these 
systems in form of long-term social health care 
has not been established yet despite many 
attempts (Barták & Gavurová, 2014; Gavurová 
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& Vagašová, 2016). A substantial portion of 
services is still provided informally by family 
members and other caregivers in households. 
This area has not been much researched yet 
(Šoltés & Gavurová, 2014). A smaller part is 
then a subject of commercial interest within the 
so-called grey economy.
There are only few specifi c data on the issue 
of dementia and associated costs which are 
publically available. Therefore, it is very diffi cult 
to draw a specifi c picture of fi nancial burden 
on the systems in European countries. The 
purpose of this article is thus to provide more 
detailed information about the current value 
of the direct costs of the treatment and care 
about patients with PD. They are calculated 
not only on the basis of aggregated data from 
the publically available sources, but also on the 
basis on authors’ own survey.
1. Methodology
In this study Drummond’s methodology 
(Drummond & O’Brien, 1997) is used for the 
specifi cation of costs. In this methodology the 
costs are divided into two categories – direct 
and indirect costs. This study is focused on the 
direct costs, especially costs of outpatient and 
inpatient care, costs of drugs. The data were 
collected on the basis of guided interviews 
run by head of the Department of Neurology. 
Partial data on outpatient and inpatient care 
are specifi ed. The data for the costs of drugs 
are based on (Winter et al., 2010) and they are 
included in the fi nal amount in conclusion so 
that there could be an opportunity to compare 
the direct costs with other EU countries. 
510 with patients participated in this study 
in the period of 2011-to the third quarter of 
2015. The data were collected at the University 
Hospital in Hradec Kralove in the Czech 
Republic as one of the countries of Central 
Europe. The study focuses on the following 
parameters: length of hospitalization, price of 
hospitalization, number and types of outpatient 
examinations. The data are sorted and values 
of descriptive statistics are specifi ed such as 
average, maximum minimum, mean, deviation.
The results refer to the diagnoses according 
to the International Statistical Classifi cation of 
Diseases and Related Health Problems. The 
attention is focused on Parkinson’s disease 
dementia (G20+). 510 in the category G20 are 
included. Secondary Parkinsonism (G21) and 
Parkinsonism in diseases fi led elsewhere (G22) 
are not analysed. For category G21 only the 
numbers of patients are described, for category 
G22 no patients are in University of Hospital in 
analysed period.
2. Treatment Costs of Parkinson’s 
Disease in Central Europe – 
a Czech Cohort Study
In the Czech Republic the total number of 
patients with PD is estimated at 16,000 people. 
The incidence, however, gradually increases 
with age and in the age categories at 65 years it 
affects 1-2% of population. The General Health 
Insurance Company (GHIC), which covers 
costs of most patients in the Czech Republic, 
reported in 2014 almost 16,000 patients with 
PD. Their treatment reached nearly 14,782,966 
EUR (CZK/EURO – exchange rate is based on 
data from the European Central Bank accessed 
14th March, 2016).
The biggest fi nancial share is formed by 
the costs of commonly used prescribed drugs 
within the outpatient care (more than 52%). 
Almost 10% is then created by the costs of 
Duodopa (“Všeobecná Zdravotní Pojišťovna 
[General Health Insurance Company],” 2015). 
The costs of drugs per patient for the Czech 
Republic were specifi ed in (Winter et al., 2010) 
and it is 1,220 EUR, which is also considered 
in this study and included in the total amount of 
direct costs.
2.1 Characteristics of Patients
Table 1 presents numbers of patients, who 
were registered at the University Hospital of 
Hradec Kralove in the monitored period with 
individual diagnosis and numbers of outpatient 
examinations. Attention is only paid to the 
patients in category G20, whose number is 510.
2.2 Costs of Outpatient Care
One of the items of the direct costs are the 
costs of outpatient care. This study involves 
the costs of individual visits such as a visit at 
the neurologist, blood collection, CT head or 
body native and contrastive screening as it is 
presented in Table 2.
The visits at the neurologist can be twice 
a year, but according to the patient’s state also 
three-four times a year. The calculation of the 
costs is based on a model example of two 
special examinations by a neurologist per year, 
one complex examination by a neurologist, one 
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targeted examination by a neurologist, blood 
collections twice a year, CT head screening 
once a year. The total fi nal amount is 144 EUR. 
Additional costs include the costs of drugs 
(modifi ed according to (Winter et al., 2010) at 
average amount of 1,220 EUR per year. The 
total annual costs of outpatient treatment are 
1,364 EUR.
2.3 Costs of Inpatient Care
The number of patients in relation to the length 
of hospitalisation and costs are described in 
Table 3.
The costs and the length of hospitalization 
are signifi cantly infl uenced by the fact whether 
the patient spent some time at the Intensive 
Care Unit (ICU) or not. The costs without 
the stay at ICU and with the stay at ICU are 
presented in Table 4.
The days of hospitalization and the costs of 
hospitalization for individual years and all the 
patients with standard deviation are described 
in Table 5.
The costs of inpatient care range in the 
individual years between 407 and 1,239 EUR 























2011 136 371 2.73 3 4 1.33
2012 99 301 3.04 4 7 1.75
2013 99 258 2.61 5 7 1.40
2014 89 202 2.27 7 11 1.57
1.-9./2015 87 191 2.20 4 9 2.25
Total 510 1,323 2.59 23 38 1.65
Sources: University Hospital of Hradec Kralove (2015) and authors’ own calculations
Examination Type EUR
1st visit at the neurologist
Complex 24.91 €
Special 5.34 €




Followed person 0.38 €
Blood collection, twice a year Only if indicated by a doctor 1.37 €
CT head or body native and 
contrastive screening Only if indicated by a doctor 94.37 €
Total 144.34 €
Sources: University Hospital of Hradec Kralove (2015) and authors’ own calculations
Tab. 1: Total number of examinations and patients with dg. G20, G21 (outpatient department)
Tab. 2: Costs of outpatient care
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costs of patient per year may be modelled on 
the basis of the following relationship:
  Average outpatient care per patient + Drugs 
+ Average inpatient care per patient,
   Thus = 144 +1,220 + 686 = 2,032 €.
Not every patient has to be hospitalized 
during the year, but the hospitalization at ICU 
signifi cantly infl uences the costs and it does not 
have to be directly connected with Alzheimer’s 
disease. In that case the costs could be lowered 
by 686 EUR (CZK/EUR – exchange rate is 
based on data from the European Central Bank 
accessed 14th March, 2016).
3. Discussion
Within this study the outpatient and inpatient 
costs of PD in Central European country – 
Czech Republic were monitored. The authors 
Days of hospitalization Number of patients 




less than 1 week 39 less than 400 38
to 2 weeks 56 to 700 64
to 3 weeks 13 to 1,700 8
more than 4 weeks 6 more than 1,700 4
Sources: University Hospital of Hradec Kralove (2015) and authors’ own calculations
Tab. 3: Days and costs of hospitalization
Year Number of days Total cost (EUR) Average costs per day (EUR)
2011 146 7,018.9 48.1
2012* 122 5,784.6 47.4
2013* 260 12,115.1 46.6
2014* 354 15,923.4 45.0
1.-9./2015 199 9,200.4 46.2
Total* 1,081 50,042.5 46.3
*These data do not include the patients who had to be hospitalized at ICU.
 
Patients hospitalized at ICU  
Year Number of days (ICU) Total cost (ICU)(EUR)
Average cost per day 
(ICU) (EUR)
2012 33 12,812.2 371.0
2013 14 4,770.6 294.2
2014 15 3,967.6 219.5
Total 62 21,550.4 317.0
Sources: University Hospital of Hradec Kralove (2015) and authors’ own calculations
Tab. 4: Costs with respect to the stay at ICU
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researched the direct costs among 510 patients 
at the University Hospital of Hradec Kralove 
were explored in the period of 2011- to the third 
quarter of 2015. They included neurological 
examination, CT screening, blood collection, 
hospitalization, and drugs. The total costs 
reached a value of 2,032 EUR.
According to (von Campenhausen et al., 
2011), the total costs per patient in the Czech 
Republic were monitored. If only the amounts 
comparable with this survey are selected, it is 
possible to observe almost the identical costs 
of prices of examination and hospitalization per 
patient (Tab. 6). 
Furthermore, within a comparison with 
other foreign studies (Andlin-Sobocki, Jönsson, 
Wittchen, & Olesen, 2005), (Spottke et al., 
2005), (Hagell, Nordling, Reimer, Grabowski, 
& Persson, 2002), (Findley et al., 2003) the 
length of hospitalization can be discussed. 
For example, an average length of the stay of 
the hospitalized patients ranged between eight 
days in Austria to 19 days in Germany during the 
six-month observation (von Campenhausen et 
al., 2011). In the Czech Republic it is about 10 
days. The costs connected with the hospitalized 
patients (including the hospitalization and 
rehabilitation) differed in the selected 
Hospitalization The days of hospitalization
Costs of hospitalization 
(EUR)
        Year M ± SD M ± SD
2011
(n = 15) 8.47 ± 3.62 406.6 ± 161.3
Range 1 day ─ 14 days 59.7 ─ 657.0
2012
(n = 15) 11.1 ± 5.76 1,239.8 ± 2,321.3
Range 3 days ─ 28 days 177.1 ─ 9,021.7
2013
(n = 26) 11.07 ± 6.19 649.5 ± 865.6
Range 1 day ─ 28 days 60.1 ─ 4,770.6
2014
(n = 34) 11.29 ± 7 585.0 ± 521.0
Range 3 days ─ 40 days 156.4 ─ 311.6
1.-9./2015
(n = 20) 9.95 ± 5.717 460.0 ± 234.1
Range 3 days ─ 24 days 145.4 ─ 1,024.6
Total
(n = 110) 10.59 ± 6.02 642.5 ± 1,011.4
Range 1 day ─ 40 days 59.7 ─ 9,021.7
Sources: University Hospital of Hradec Kralove (2015) and authors’ own calculations
Costs of PD in Czech Republic in 2008, source: 
(von Campenhausen et al., 2011), in EUR
Own study – costs of PD in the Czech 
republic in 2011-2015, in EUR
Hospitalization per one patient/per day 70 Hospitalization 51.8
GP (2x) and Neurologist (2x) 14 + 24 = 38 Neurologist four times a year 49
Total 108 100.7
Source: authors
Tab. 5: Overview of the costs of inpatient establishments in the period of 2011-2015, diagnosis G20
Tab. 6: Comparison of the selected direct costs
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countries from 100 EUR to 1,600 EUR. In 
the Czech Republic the costs connected with 
hospitalization are about 700 EUR. Thus, one 
can see that the costs of hospitalization as well 
as its length in the Czech Republic are average.
Table 7 compares the costs of the selected 
direct costs in the selected European countries: 
Inpatient care +Outpatient care + drugs. The 
amounts of the direct costs from other studies 
are calculated on the basis of (Andlin-Sobocki 
et al., 2005), where direct costs -the individual 
items are as follows: 41% home care, 11% 
drugs, 3% hospitalized care, other direct costs 
5%. Thus, this study considers 19% of the total 
costs (without home care).
These costs from all studies are converted 
into the period of 12 months with respect to 
the possibility of their comparison with other 
studies.
As Table 7 above shows, the highest direct 
costs per patient per year are defi nitely in the 
United Kingdom, followed by Germany and 
Sweden. On the contrary, the lowest direct 
costs per patient are in Italy and Austria. The 
Czech Republic again stands somewhere in 
the middle. As far as the selected direct costs 
(inpatient care, outpatient care and drugs) are 
concerned, the Czech Republic on the basis of 
this study comes fi rst, followed by the United 
Kingdom and Germany. Italy again comes last. 
The results of this study is particularly infl uenced 
by the costs on inpatient care, including the 
stays at ICU, which signifi cantly affect the 
prices. In other studies this specifi c information 
on the types of hospitalization is not included. 
In case of lowering the data by hospitalization 
variable, the costs in the Czech Republic would 
reach 1,364 EUR, which would rank the Czech 
Republic after Germany (Tab. 7). 
The survey showed that the underpinning of 
patients with PD was benefi cial from the costs 
point of view because the costs on the outpatient 
care were much lower in comparison with the 
inpatient care. In addition, patients released 
from the hospital are usually transferred to 
the establishments with subsequent care, for 
example into hospices, because family care 
due to its complexity is impossible. In the 
individual regions of the Czech Republic there 
are substantial differences which would deserve 
detail research. Most of the patients has been 
recorded in Prague, south Moravia and central 
Bohemia. There are twofold or even threefold 
differences in the provided health services 
among the individual regions (“Všeobecná 
Zdravotní Pojišťovna [General Health Insurance 
Company],” 2015). In the regions it is not possible 
to trace more signifi cant connections and ties 
among the frequencies of individual types of 
services. Thus, one cannot argue that one form 
of service was compensated by another.
Conclusions
The information stated above shows that 
the issue of the treatment costs of PD is not 
systematically solved, except perhaps an 
Country Direct costs per one year per one patient
Direct costs (Inpatient care, 
Outpatient care and drugs) 
(19% of direct costs) 
Total costs EUR EUR
Czech Republic 6,700 (Winter et al., 2010) 1,273
Italy 5,004 (von Campenhausen et al., 2011) 950
Germany 8,160 (Spottke et al., 2005) 1,635
Austria 5,892 (von Campenhausen et al., 2011) 1,119
Sweden 7,920 (Hagell et al., 2002) 1,504
United Kingdom 9,500 (Findley et al., 2003) 1,805
Czech Republic 
(this survey) x 2,032 
Source: authors
Tab. 7: Total treatment costs in the selected European countries
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individual treatment, but not within the framework 
of individual countries so that the data could be 
compared. In spite of the distortion of the data, 
it can be claimed that the treatment costs are 
rising. With respect to the aging population in 
Europe, these items will increasingly represent 
a bigger burden of health systems. Therefore, 
emphasis should be put on the unifi ed strategy 
for their payment in individual countries. In 
addition, the authors of this study suggest 
that amount of healthcare services in all the 
country’s regions (Maresova, Klimova, & Kuca, 
2014). In addition, with respect to the rising 
treatment costs, more attention should be also 
paid to the alternative non-pharmacological 
therapies (Klimova & Kuca, 2015). Furthermore, 
international comparisons on the volume of 
provided care must be considered very carefully. 
These comparisons are usually based on expert 
estimation and they are not supported by reliable 
data (Maresova, Mohelska, Dolejs, & Kuca, 
2015). Even a more complicated comparison 
among the other EU countries is in the area 
of social care (Klimova, Maresova, Valis, Hort, 
& Kuca, 2015) because in social services in 
comparison with healthcare, there is no regular 
disclosure of information, which would deal with 
the issue of dementia.  
This study was supported by the project 
Excellence 2016 (University of Hradec Kralove, 
Faculty of Informatics and Management) and 
by the grant No. FNHK00179906 (Ministry of 
Health, Czech Republic) and program PRVOUK 
P37/08.
References
Andlin-Sobocki, P., Jönsson, B., Wittchen, 
H.-U., & Olesen, J. (2005). Cost of disorders 
of the brain in Europe. European Journal of 
Neurology, 12 Suppl 1, 1-27. doi:10.1111/
j.1468-1331.2005.01202.x.
Barták, M., & Gavurová, B. (2014). 
Economics and social aspects of long-term 
care in the context of the Czech Republic 
and the Slovak Republic EU membership. In 
Proceedings of 12th International scientifi c 
conference: Economic Policy in the European 
Union member countries, PTS I and II. (Vol. 
2015, pp. 35-44). Ostravice, Czech Republic.
Dlouhý, M., & Barták, M. (2013). Mental 
Health Financing in Six Eastern European 
Countries. E&M Ekonomie a Management, 
16(4), 4-13.
Dorsey, E. R., Constantinescu, R., 
Thompson, J. P., Biglan, K. M., Holloway, R. G., 
Kieburtz, K., Tanner, C. M. (2007). Projected 
number of people with Parkinson disease in 
the most populous nations, 2005 through 2030. 
Neurology, 68(5), 384-386. doi:10.1212/01.
wnl.0000247740.47667.03.
Drummond, M. F., & O’Brien, B. J. (1997). 
Methods for the Economic Evaluation of Health 
Care Programs (2nd ed.). Oxford Medical 
Publication.
European Parkinson’s Disease Association. 
(2015). About Parkinson’s. Retrieved July 8, 
2015, from http://www.epda.eu.com/en/pd-info/
about-parkinsons/.
Farlow, M. R., Schmitt, F., Aarsland, 
D., Grossberg, G. T., Somogyi, M., & 
Meng, X. (2013). Comparing Clinical Profi les 
in Alzheimer’s Disease and Parkinson’s 
Disease Dementia. Dementia and Geriatric 
Cognitive Disorders Extra, 3(1), 281-290. 
doi:10.1159/000351861.
Findley, L., Aujla, M., Bain, P. G., Baker, M., 
Beech, C., Bowman, C., Playfer, J. R. (2003). 
Direct economic impact of Parkinson’s disease: 
A research survey in the United Kingdom. 
Movement Disorders, 18(10), 1139-1145. 
doi:10.1002/mds.10507.
Gavurová, B., Vagašová, T. (2016). 
Regional differences of standardised mortality 
rates for ischemic heart diseases in the Slovak 
Republic for the period 1996-2013 in the context 
of income inequality. Health Economics Review, 
6(21). doi:10.1186/s13561-016-0099-1.
Hagell, P., Nordling, S., Reimer, J., 
Grabowski, M., & Persson, U. (2002). Resource 
use and costs in a Swedish cohort of patients 
with Parkinson’s disease. Movement Disorders, 
17(6), 1213-1220. doi:10.1002/mds.10262.
Klimova, B., & Kuca, K. (2015). Alzheimer’s 
disease: Potential preventive, non-invasive, 
intervention strategies in lowering the risk of 
cognitive decline – A review study. Journal 
of Applied Biomedicine, 13(4), 257-261. 
doi:10.1016/j.jab.2015.07.004.
Klimova, B., Maresova, P., Valis, M., Hort, 
J., & Kuca, K. (2015). Alzheimer’s disease and 
language impairments: social intervention and 
medical treatment. Clinical Interventions in 
Aging, 10, 1401-1408. doi:10.2147/CIA.S89714.
Maresova, P., Klimova, B., & Kuca, K. 
(2014). Alzheimers disease: cost cuts call for 
novel drugs development and national strategy. 
Ceska a Slovenska Farmacie, 64(1-2), 25-30.
EM_3_2016.indd   37 8.9.2016   14:11:00
38 2016, XIX, 3
Ekonomie
Maresova, P., Mohelska, H., Dolejs, J., 
& Kuca, K. (2015). Socio-economic Aspects 
of Alzheimer’s Disease. Current Alzheimer 
Research, 12(9), 903-911.
Ransmayr, G. (2015). Cognitive impairment 
in Parkinson’s disease. Psychiatria Danubina, 
27(4), 458-461.
Růžička, E., Roth, J., & Kaňovský, P. (2000). 
Parkinsonova nemoc a parkinsonské syndromy 
[Parkinson’s disease and parkinsonian 
syndromes]. Praha: Galén.
Spottke, A. E., Reuter, M., Machat, O., 
Bornschein, B., Campenhausen, S. von, 
Berger, K., Dodel, D. R. (2005). Cost of illness 
and its predictors for Parkinson’s disease in 
Germany. PharmacoEconomics, 23(8), 817-
836. doi:10.2165/00019053-200523080-00007.
Šoltés, V., & Gavurová, B. (2014). The 
possibilities of day surgery system development 
within the health policy in Slovakia. Health 
Economics Review, 4(35). doi:10.1186/s13561-
014-0035-1.
von Campenhausen, S., Winter, 
Y., Rodrigues e Silva, A., Sampaio, C., 
Ruzicka, E., Barone, P., Reese, J. P. (2011). 
Costs of illness and care in Parkinson’s 
disease: an evaluation in six countries. 
European Neuropsychopharmacology: The 
Journal of the European College of Neuro-
psychopharmacology, 21(2), 180-191. 
doi:10.1016/j.euroneuro.2010.08.002.
Všeobecná Zdravotní Pojišťovna [General 
Health Insurance Company]. (2015). Retrieved 
September 8, 2015, from https://www.vzp.cz/o-
nas/aktuality/.
Winter, Y., von Campenhausen, S., 
Brozova, H., Skoupa, J., Reese, J. P., Bötzel, 
K., Ruzicka, E. (2010). Costs of Parkinson’s 
disease in Eastern Europe: A Czech cohort 
study. Parkinsonism & Related Disorders, 16(1), 
51-56. doi:10.1016/j.parkreldis.2009.07.005.
Yorkston, K. M., Beukelman, D., Strand, E. 
A., & Bell, K. R. (1999). Management of Motor 
Speech Disorders in Children and Adults (2nd 
ed.). Austin, Tex: Pro ed.
doc. Ing. Mgr. Petra Marešová, Ph.D.
University of Hradec Kralove
Faculty of Informatics and Management
Department of Economy
petra.maresova@uhk.cz
doc. PhDr. Blanka Klímová, M.A., Ph.D.
University of Hradec Kralove
Faculty of Informatics and Management
Department of Linguistics
blanka.klimova@uhk.cz
doc. MUDr. Martin Vališ, Ph.D.
Charles University in Prague
Faculty of Medicine in Hradec Kralove
& University Hospital Hradec Kralove
Department of Neurology
valismar@seznam.cz
prof. Ing. Kamil Kuča, Ph.D.
University of Hradec Kralove
University Hospital Hradec Kralove
Faculty of Informatics and Management
Biomedical Research Centrum
Center for Basic and Applied Research
kamil.kuca@fnhk.cz
doc. Ing. Hana Mohelská, Ph.D.
University of Hradec Kralove
Faculty of Informatics and Management
Department of Management
hana.mohelska@uhk.cz




TREATMENT COSTS OF PARKINSON’S DISEASE IN CENTRAL EUROPE
Petra Marešová, Blanka Klímová, Martin Vališ, Kamil Kuča, Hana Mohelská
The aim of the study is to describe current values of direct costs of Parkinson’s disease in western 
and central Europe in comparison with other available data in order to illustrate the development 
of the treatment costs of Parkinson’s disease (PD) on the public sector.
In this research study Drummond’s methodology is used for the specifi cation of costs. The costs 
are divided into two categories. The fi rst category consists of the costs of creation and running of 
health care program and these costs are perceived as the used sources. The costs are calculated 
on the basis of the reviews of the studies from the European countries, but also on the basis 
of authors’ own survey in the University Hospital of Hradec Kralove conducted among 510 patients 
in the period of 2011-to the third quarter of 2015.
Within this study the direct costs among 510 patients at the University Hospital of Hradec 
Kralove were explored in the period of 2011- to the third quarter of 2015. These costs included 
neurological examination, CT screening, blood collection, hospitalization, and drugs. The total 
direct costs of patient per year reached 2,032 EUR.
The survey showed that the underpinning of patients with PD was benefi cial from the costs point 
of view because the costs on the outpatient care were much lower in comparison with the inpatient 
care. In addition, patients released from the hospital are usually transferred to the establishments 
with subsequent care, for example into hospices, because family care due to its complexity is 
impossible.
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